← back to search

Michael A. Thompson

University of California, Los Angeles · US
Area of research
Physiology · Oncology
Research interest
Research interests include Asthma and respiratory diseases, COVID-19 and healthcare impacts, Ion Channels and Receptors, and Cancer Genomics and Diagnostics.
h-index
60
citations
15,150
works
611
NIH funding
primary concept
Medicine
email

Recent publications

DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer
Lung Cancer 2025cited by 5position: middledoi
DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer.
2025cited by 1position: contributordoi
Exploratory evaluation of the somatic and immunologic landscape of primary and metastatic cervical cancer to better inform future clinical trial development.
2025cited by 0position: contributordoi
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
Communications Medicine 2023cited by 32position: middledoi
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
2023cited by 21position: contributordoi
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.
2023cited by 8position: contributordoi
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
medRxiv 2023cited by 0position: middledoi
Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
2023cited by 0position: contributordoi
Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
2023cited by 0position: contributordoi
Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
2023cited by 0position: contributordoi
Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
2023cited by 0position: contributordoi
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
JAMA Network Open 2022cited by 71position: middledoi
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
JAMA Oncology 2022cited by 62position: middledoi
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
2022cited by 41position: contributordoi
Online Medical Misinformation in Cancer: Distinguishing Fact From Fiction.
2022cited by 34position: contributordoi
Social Media and Professional Development for Oncology Professionals.
2022cited by 13position: contributordoi
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.
2022cited by 12position: contributordoi
Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance.
2022cited by 7position: contributordoi
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma.
2022cited by 6position: contributordoi
HealthTree Cure Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles and Accelerate Research in Multiple Myeloma.
2022cited by 2position: contributordoi
Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profiling
2022cited by 0position: contributordoi
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Annals of Oncology 2021cited by 326position: middledoi
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
JAMA Oncology 2021cited by 184position: firstdoi
Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization’s Response for Readiness, Mitigation, and Resilience
JCO Oncology Practice 2021cited by 67position: middledoi
COVID-19 and Cancer
JAMA Oncology 2021cited by 54position: lastdoi
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer
Journal of Clinical Oncology 2021cited by 51position: middledoi
Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization's Response for Readiness, Mitigation, and Resilience.
2021cited by 49position: contributordoi
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples
JCO Precision Oncology 2021cited by 33position: middledoi
The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19
Journal of Thrombosis and Haemostasis 2021cited by 30position: middledoi
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples
JCO Precision Oncology 2021cited by 23position: contributordoi

Grants

Collaborative Research: Mapping and comparing the link of the protein scaffold to quantum events in thermally activated enzymes and flavin-based photoreceptors
NSF2231082$384,5492023–2027PIRePORTER
Collaborative Research: Stabilized Organic Carbon and Paleoenvironmental Interpretations of Late Quaternary Paleosols
NSF1226949$117,3772012–2016PIRePORTER
NeTS: Small: Collaborative Research: The Flexible Internetwork Stack (FINS) Framework
NSF0916283$150,5402009–2013PIRePORTER
NSF East Asia Summer Institutes for US Graduate Students
NSF0513138$3,0002005–2006PIRePORTER
Presidential Young Investigator Award
NSF8351514$277,0001984–1990PIRePORTER

Frequent collaborators

· 15 papers (2020–2025)Don S. Dizon · Worldwide Clinical Trials (United States)3 papers (2020–2021)Jeremy L. Warner · Providence Center3 papers (2020–2021)Aakash Desai · University of Alabama at Birmingham3 papers (2020–2021)Scott A. Tomlins · Stratasys (Israel)3 papers (2021–2023)Nicole M. Kuderer · Advanced Dermatology2 papers (2020–2021)Dimpy P. Shah · Topiwala National Medical College & BYL Nair Charitable Hospital2 papers (2020–2020)Karen L. Reckamp · Molecular Oncology (United States)2 papers (2025–2025)Solange Peters · Hôpital Beau-Séjour2 papers (2020–2021)W. E. Moerner · Palo Alto University2 papers (2012–2012)Gary H. Lyman · Fred Hutch Cancer Center2 papers (2020–2021)Areej El‐Jawahri · Harvard University2 papers (2021–2021)Gijsberta J van Londen · University of Pittsburgh2 papers (2022–2022) · 2 papers (2020–2021)Khalis Mitchell · Johns Hopkins University2 papers (2021–2023)Emily K. Drake · Dalhousie University2 papers (2022–2022)Melissa Shreve · American Society for Clinical Pathology2 papers (2022–2023)Abby R. Rosenberg · The University of Texas Health Science Center at San Antonio2 papers (2020–2021) · 2 papers (2022–2022)Brian I. Rini · Cancer Research UK2 papers (2020–2021)